Jul. 31 at 3:51 AM
$COSM COSM Cosmos Health quietly having a strong 2026 - prelim Q2 revenue came in around
$19.4M, up ~31.5% YoY, and H1 revenue was ~
$37.3M, up ~31% YoY, driven by their Sky Premium Life and Mediterranation brands plus expanding distribution deals like the Pharma Cell partnership in Albania (54k+ annualized units projected). Management’s also been buying back stock consistently in the
$0.25-
$0.28 range, over 4.8M shares repurchased for ~
$1.04M so far under a program authorized up to
$5M through year end, and they’ve said publicly they think shares trade below intrinsic value. Combine growing top-line revenue with insiders/company putting real money into buybacks at these levels and it’s a name worth having on your radar.
$INLF $CPOP $BTC.X
$CYCU
